home / stock / ngm / ngm news

NGM News and Press, NGM Biopharmaceuticals Inc. From 02/26/24

Stock Information
Company Name: NGM Biopharmaceuticals Inc.
Stock Symbol: NGM
Market: NYSE
Menu
NGM NGM Quote NGM Short NGM News NGM Articles NGM Message Board
Get NGM Alerts

News, Short Squeeze, Breakout and More Instantly...
NGM - NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP

NGM Bio stockholders to receive $1.55 per share in cash, an 80% premium over the closing share price on the last trading day prior to disclosure of receipt from The Column Group of a non-binding expression of interest in purchasing shares in a going-private transaction Based on a thorough...
NGM - NGM Bio to Participate in the Cowen 44th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will particip...

NGM - NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and Jean-Fr&#...

NGM - NGM Biopharma gains on Phase 1 data update for cancer therapy

2024-01-09 13:24:45 ET More on NGM Biopharmaceuticals NGM Biopharma jumps on take-private offer Seeking Alpha’s Quant Rating on NGM Biopharmaceuticals Historical earnings data for NGM Biopharmaceuticals Financial information for NGM Biopharmaceuticals ...
NGM - NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need

Encouraging findings in heavily pretreated patients in multiple solid tumor indications, including MSS colorectal cancer (CRC), in ongoing Phase 1 Part 1b study evaluating NGM707, a dual ILT2/ILT4 antagonist antibody, in combination with KEYTRUDA ® (pembrolizumab) Aldafermin, an ...

NGM - NGM Biopharma jumps on take-private offer

2024-01-02 13:56:40 ET More on NGM Biopharmaceuticals Seeking Alpha’s Quant Rating on NGM Biopharmaceuticals Historical earnings data for NGM Biopharmaceuticals Financial information for NGM Biopharmaceuticals For further details see: NGM Biopharma...

NGM - NGM Biopharmaceuticals 10% owner Column Group discloses purchase of over 22K shares

2023-11-20 11:51:39 ET More on NGM Biopharmaceuticals Seeking Alpha’s Quant Rating on NGM Biopharmaceuticals Historical earnings data for NGM Biopharmaceuticals Financial information for NGM Biopharmaceuticals For further details see: NGM Biopharma...
NGM - NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®

-- As previously reported, the ALPINE 4 study met its primary endpoint, with aldafermin 3 mg demonstrating a statistically significant reduction in Enhanced Liver Fibrosis (ELF) score compared to placebo after 48 weeks of treatment -- -- ELF, an FDA-approved non-invasive blood...

NGM - NGM Biopharmaceuticals GAAP EPS of -$0.35 beats by $0.05, revenue of $0.58M misses by $2.02M

2023-11-02 17:59:38 ET More on NGM Biopharmaceuticals Seeking Alpha’s Quant Rating on NGM Biopharmaceuticals Historical earnings data for NGM Biopharmaceuticals Financial information for NGM Biopharmaceuticals For further details see: NGM Biopharma...

NGM - NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights

--Jean-Frédéric Viret, Ph.D., has been appointed as Chief Financial Officer effective November 3, 2023-- --Continued to progress myeloid checkpoint solid tumor programs: NGM707, NGM831 and NGM438-- --Selected for an oral plenary presentation of data from Phase 2b ALPIN...
Previous 10 Next 10